Name

Allosteric ErbB Inhibitor BDTX-189

Alternate Names

EGFR/HER2 inhibitor BDTX-189
ErbB mutant-specific inhibitor BDTX-189

Abbreviations

BDTX-189

Category

Chemotherapy

Subcategory

EGFR/HER2 Inhibitor

NSC Number

None

Primary Site

None

Histology

None

Remarks

July 2020: BDTX-189 has received Fast Track Designation from FDA for the treatment of adult patients with solid tumors harboring an allosteric human epidermal growth factor receptor 2 mutation or an epidermal growth factor receptor or HER2 Exon 20 insertion mutation who have progressed following prior treatment and who have no satisfactory treatment options.

Coding

This drug should be coded
Glossary